Drug Shortage Report for TOBRAMYCIN INJECTION
Report ID | 164261 |
Drug Identification Number | 02230640 |
Brand name | TOBRAMYCIN INJECTION |
Common or Proper name | TOBRAMYCIN INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | TOBRAMYCIN |
Strength(s) | 40MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 2mL |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-07-01 |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2022-10-03 |
Company comments | Effective July 1, 2022 our Tobramycin Injection 40 mg/mL MD Vial 2 mL will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2022-10-03 | French | Compare |
v8 | 2022-10-03 | English | Compare |
v7 | 2022-10-02 | French | Compare |
v6 | 2022-10-02 | English | Compare |
v5 | 2022-08-04 | French | Compare |
v4 | 2022-08-04 | English | Compare |
v3 | 2022-07-07 | French | Compare |
v2 | 2022-07-07 | French | Compare |
v1 | 2022-07-07 | English | Compare |
Showing 1 to 9 of 9